Saturday 17 October 2026 Export INBS’s income statement to Excel — free account

Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc.’s revenue for fiscal 2026 (year ended June 2026) was $4.2 million, up 38.1% from fiscal 2025. In the quarter to June 2026, revenue grew 51.1%, EPS grew 78.1% and free cash flow fell 31.6%, each against the same quarter a year earlier.

1.50 0.06 +4.17%

Follow INBS

Alert me

Market cap: $4.8M
P/E: 0.0×
Fwd P/E: 5.4×
Dividend yield: —
F-score: 5/9
Altman Z: −11.40
Beneish M: −2.45
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 4.78

Revenue 4.22

Net Income (12.47)

Free Cash Flow (12.22)

Net Debt (3.99)

Current Ratio 1.44

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 5.37

P/S ratio 0.52

P/B ratio 0.42

Past 5Y EPS Growth —

This Y EPS Growth 38.63%

Next Y EPS Growth 21.62%

Next Y revenue growth 44.71%

Next 5Y EPS Growth 30.20%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 5.02%

10-year low 10-year high

P/B against its own 10 years 10.52%

10-year low 10-year high

EV/Sales against its own 10 years 1.33%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	2	6	1	4
Receivables	1	1	1	2
Inventory	1	1	1	0
Other	1	0	1	1
	4	9	4	7

	2023	2024	2025	2026
Payables	3	2	5	4
ST’ Debt	2	2	—	—
Other	0	0	1	1
	6	5	5	5

Compound Annual Growth %

	10y	5y	3y
Sales	—	16.31%	28.33%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(18.82%)	12.79%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	1	1	1	1	4
’25	1	1	1	1	3
’24	1	1	1	1	3
’23	0	0	0	1	2
’22	—	0	0	0	0
’21	0	0	0	2	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(3)	(2)	(4)	(3)	(12)
’25	(2)	(2)	(3)	(2)	(10)
’24	(1)	(3)	(2)	(3)	(10)
’23	(2)	(2)	(3)	(1)	(7)
’22	0	(1)	0	(2)	(3)
’21	(3)	(1)	(6)	(2)	(11)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(3)	(2)	(4)	(3)	(12)
’25	(2)	(2)	(3)	(2)	(10)
’24	(1)	(3)	(2)	(3)	(10)
’23	(2)	(2)	(3)	(1)	(8)
’22	0	(1)	0	(2)	(4)
’21	(3)	(1)	(6)	(2)	(11)

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(3.50)	(2.82)	(1.80)	(0.90)	(8.44)
’25	(7.00)	(5.00)	(4.40)	(4.10)	(20.00)
’24	(124.85)	(20.70)	(14.30)	96.45	(63.80)
’23	(195.90)	(55.22)	(686.67)	(334.03)	(1.27k)
’22	(240.10)	(552.22)	(216.09)	(336.13)	(1.37k)
’21	(299.61)	(552.22)	(648.26)	(134.10)	(1.63k)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	—	—	—	16,872.00	3,024.00	408.00	24.00	10.00	4.03	1.35	Analyst estimates 2027–2029 Powerpack
	High	—	—	—	34,176.00	23,112.00	4,752.00	3,840.00	117.00	27.50	24.90
People
People	Employees	—	—	—	—	9	12	17	13	14	15
	Revenue/emp, $m	—	—	—	0.00	0.22	0.04	0.12	0.24	0.22	0.28
Income, $m
Income, $m	Revenue	—	—	—	0	2	0	2	3	3	4
	Gross margin, %	—	—	—	100.00	100.00	100.00	53.36	45.81	40.85	48.63
	EBT	0	(5)	(7)	(3)	(7)	(8)	(11)	(10)	(11)	(12)
	EBT margin, %	0.00	0.00	0.00	(1,692.10)	(356.49)	(1,906.66)	(534.70)	(327.49)	(347.42)	(295.80)
	Net income	0	(5)	(7)	(3)	(7)	(8)	(11)	(10)	(11)	(12)
	Depreciation	—	—	—	—	—	—	5	1	1	1
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	53.91	460.58	71.66	237.44	19.53	5.79	2.86
	Earnings	(0.03)	(0.42)	(12.15)	(900.84)	(1,632.65)	(1,368.55)	(1,270.11)	(63.80)	(20.00)	(8.44)
	Cash flow	(0.02)	(0.45)	(9.23)	(142.46)	(2,627.09)	(550.49)	(878.26)	(60.09)	(18.35)	(8.10)
	Capex	0.00	0.00	0.00	0.00	0.00	(62.33)	(60.13)	(1.39)	(0.44)	(0.06)
	Free cash flow	(0.02)	(0.45)	(9.23)	(142.46)	(2,627.09)	(612.82)	(938.39)	(61.48)	(18.79)	(8.16)
	Book value	(0.49)	(0.36)	(7.64)	(1,489.94)	3,489.91	1,073.08	438.93	51.37	5.34	3.59
	Shares, m	12	12	1	0	0	0	0	0	1	1
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	0.00	20.53	4.36	1.22	0.94	2.97	0.80
	P/B	—	—	—	0.00	2.71	1.48	0.76	0.36	3.22	0.64
	EV/Sales	—	—	—	0.00	15.24	1.93	1.74	(0.24)	3.43	0.43
	EV/FCF	—	—	—	(29.98)	(2.67)	(1.28)	(0.51)	0.08	(1.04)	(0.15)
Cash, $m
Cash, $m	Operating cash flow	0	(5)	(6)	0	(11)	(3)	(7)	(10)	(10)	(12)
	Capex	—	—	—	—	—	0	(1)	0	0	0
	Free cash flow	0	(5)	(6)	0	(11)	(4)	(8)	(10)	(10)	(12)
Balance, $m
Balance, $m	Working capital	(7)	(5)	(6)	(5)	15	6	(2)	3	(1)	2
	Total debt	6	5	5	5	2	3	3	2	—	—
	Net debt	6	4	5	5	(10)	(5)	1	(4)	(1)	(4)
	Shareholders’ equity	(6)	(4)	(5)	(5)	15	7	4	8	3	5
Returns, %
Returns, %	ROA	0.00	(402.29)	(304.18)	(131.73)	(57.84)	(48.56)	(93.64)	(84.17)	(95.95)	(123.13)
	ROIC	0.00	0.00	0.00	0.00	(76.87)	(455.43)	(160.96)	(147.21)	(372.07)	(606.86)
	ROE	0.00	52.84	44.82	25.43	(144.28)	(77.12)	(207.80)	(171.13)	(192.21)	(306.76)

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
WOK WORK Medical Technology Group LTD	$6.0M	—	—	—	—	−948.94% (below 0%: shrinking)	—	—	Compare
AMIX Autonomix Medical, Inc.	$5.7M	— (loss-making)	—	—	n/m	−36.10% (below 0%: shrinking)	—	0.00%	Compare
NVNO enVVeno Medical Corporation	$5.5M	— (loss-making)	— (loss-making)	+0.32% (above 0%: growing)	n/m	+4.60% (above 0%: growing)	0.00%	0.00%	Compare
CODX Co-Diagnostics, Inc.	$5.3M	— (loss-making)	— (loss-making)	+1.96% (above 0%: growing)	n/m	+17.47% (above 0%: growing)	72.73%	(3,733.17%)	Compare
TBIO Telesis Bio Inc.	$5.3M	— (loss-making)	— (loss-making)	−61.79% (below 0%: shrinking)	n/m	−17.96% (below 0%: shrinking)	64.43%	(349.74%)	Compare
VNRX VolitionRX Limited	$5.3M	— (loss-making)	— (loss-making)	−1.97% (below 0%: shrinking)	n/m	+18.58% (above 0%: growing)	100.00%	(1,042.39%)	Compare
TRIB Trinity Biotech PLC	$5.1M	— (loss-making)	— (loss-making)	+43.28% (above 0%: growing)	n/m	+75.24% (above 0%: growing)	35.43%	(24.53%)	Compare
VVOS Vivos Therapeutics, Inc.	$4.8M	— (loss-making)	— (loss-making)	+34.90% (above 0%: growing)	n/m	+16.44% (above 0%: growing)	57.31%	(93.63%)	Compare
INBS Intelligent Bio Solutions Inc.	$4.8M	— (loss-making)	5.4×	+51.10% (above 0%: growing)	n/m	−31.59% (below 0%: shrinking)	43.23%	(360.19%)
Median of peers	$5.3M	—	—	+1.14%	—	+10.52%	60.87%	(93.63%)

All 149 Medical Devices stocks →

Intelligent Bio Solutions Inc. (INBS) key facts

Strength: Intelligent Bio Solutions Inc.’s revenue for fiscal 2026 (year ended June 2026) was $4.2 million, up 38.1% from fiscal 2025.
Intelligent Bio Solutions Inc. (INBS) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, INBS traded at $1.50, a market capitalization of $4.8 million.
Return on equity was −306.8% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −11.40 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.